Uwe Kordes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/657978/publications.pdf

Version: 2024-02-01

69 papers	2,537 citations	257450 24 h-index	197818 49 g-index
71 all docs	71 docs citations	71 times ranked	3595 citing authors

#	Article	IF	Citations
1	Spatial molecular profiling of a central nervous system lowâ€grade diffusely infiltrative tumour with INI1 deficiency featuring a highâ€grade atypical teratoid/rhabdoid tumour component. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	7
2	Final results of the Choroid Plexus Tumor study CPT-SIOP-2000. Journal of Neuro-Oncology, 2022, 156, 599-613.	2.9	11
3	Lowâ€grade diffusely infiltrative tumour (LGDIT), SMARCB1â€mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRTâ€MYC. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	5
4	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. Pediatric Blood and Cancer, 2022, 69, e29594.	1.5	0
5	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. American Journal of Surgical Pathology, 2022, 46, 1277-1283.	3.7	3
6	ATRTâ€“SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance. Acta Neuropathologica, 2022, 143, 697-711.	7.7	13
7	Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population. Cancers, 2022, 14, 2185.	3.7	9
8	ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. Neuro-Oncology, 2022, 24, i3-i4.	1.2	0
9	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
10	DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge. Neuro-Oncology, 2022, 24, i28-i28.	1.2	0
11	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations andTP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i4-i4.	1.2	0
12	Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 327-336.	1.9	13
13	The genetic landscape of choroid plexus tumors in children and adults. Neuro-Oncology, 2021, 23, 650-660.	1.2	26
14	Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). European Journal of Cancer, 2021, 142, 112-122.	2.8	15
15	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 2021, 141, 291-301.	7.7	47
16	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	1.9	20
17	Atypical Teratoid/Rhabdoid Tumor (AT/RT) With Molecular Features of Pleomorphic Xanthoastrocytoma. American Journal of Surgical Pathology, 2021, 45, 1228-1234.	3.7	5
18	Transposable element insertion as a mechanism of <scp>SMARCB1</scp> inactivation in atypical teratoid/rhabdoid tumor. Genes Chromosomes and Cancer, 2021, 60, 586-590.	2.8	5

#	Article	IF	Citations
19	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. Acta Neuropathologica, 2021, 142, 361-374.	7.7	6
20	<scp>SMARCA4</scp>â€deficient rhabdoid tumours show intermediate molecular features between <scp>SMARCB1</scp>â€deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. Journal of Pathology, 2021, 255, 1-15.	4.5	14
21	Evidence for a lowâ€penetrant extended phenotype of rhabdoid tumor predisposition syndrome 1 from a kindred with gain of SMARCB1 exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
22	Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome. Acta Neuropathologica, 2021, 142, 591-593.	7.7	5
23	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
24	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathologica, 2020, 139, 277-286.	7.7	36
25	Epigenetics impacts upon prognosis and clinical management of choroid plexus tumors. Journal of Neuro-Oncology, 2020, 148, 39-45.	2.9	10
26	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
27	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. Acta Neuropathologica, 2019, 137, 847-850.	7.7	7
28	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	4.1	27
29	Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1. Anticancer Research, 2019, 39, 827-831.	1.1	4
30	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. European Journal of Human Genetics, 2018, 26, 1083-1093.	2.8	30
31	Differences in maxillomandibular morphology among patients with mucopolysaccharidoses I, II, III, IV and VI: a retrospective MRI study. Clinical Oral Investigations, 2018, 22, 1541-1549.	3.0	6
32	Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a. Child's Nervous System, 2018, 34, 581-584.	1.1	2
33	EMBR-08. CHOROID PLEXUS TUMORS IN 2018: THE CPT-SIOP EXPERIENCE AND LONG-TERM OUTCOME. Neuro-Oncology, 2018, 20, i70-i70.	1.2	3
34	Coâ€occurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1. Molecular Genetics & Genomic Medicine, 2018, 6, 627-637.	1.2	13
35	ATRT-06. CLINICAL AND MOLECULAR RISK FACTORS IN CHILDREN WITH ATYPICAL TERATOID/RHABDOID TUMOUR (AT/RT) - EVIDENCE FROM THE EU-RHAB REGISTRY. Neuro-Oncology, 2018, 20, i28-i28.	1.2	0
36	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncology, The, 2018, 19, e419-e428.	10.7	16

#	Article	IF	Citations
37	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
38	Updated dataset of germline mutations within the SWI/SNF complex predicting age of tumor onset and type of disease. Klinische Padiatrie, 2017, 229, .	0.6	0
39	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro-Oncology, 2016, 18, 790-796.	1.2	67
40	Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children. Acta Neuropathologica, 2015, 129, 925-927.	7.7	35
41	PTCT-01INTERCONTINENTAL MULTIDISCIPLINARY DATA COLLECTION AND TREATMENT OPTIMIZATION STUDY FOR PATIENTS WITH CHOROID PLEXUS TUMORS. Neuro-Oncology, 2015, 17, v186.1-v186.	1.2	3
42	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
43	High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors. Journal of Neuropathology and Experimental Neurology, 2015, 74, 110-120.	1.7	31
44	Radiation therapy for choroid plexus carcinoma patients with Li-Fraumeni syndrome: advantageous or detrimental?. Anticancer Research, 2015, 35, 3013-7.	1.1	21
45	Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatric Blood and Cancer, 2014, 61, 919-921.	1.5	41
46	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplantation, 2014, 49, 370-375.	2.4	58
47	Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis. Genes Chromosomes and Cancer, 2014, 53, 373-380.	2.8	43
48	Methylation of the hTERT promoter is frequent in choroid plexus tumors but not of independent prognostic value. Journal of Neuro-Oncology, 2014, 119, 215-216.	2.9	11
49	Neuroonkologie. , 2014, , 277-304.		0
50	Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression. Journal of Neuro-Oncology, 2013, 112, 191-197.	2.9	12
51	Highâ€resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes and Cancer, 2013, 52, 185-190.	2.8	138
52	Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents. Journal of Neuro-Oncology, 2012, 109, 449-455.	2.9	11
53	Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. Journal of Neuro-Oncology, 2012, 107, 139-146.	2.9	29
54	A complex karyotype in an atypical teratoid/rhabdoid tumor: case report and review of the literature. Journal of Neuro-Oncology, 2011, 104, 375-380.	2.9	20

#	Article	IF	Citations
55	Parvovirus B19 infection and autoimmune hepatitis in a child with sickle cell anemia. Pediatric Blood and Cancer, 2011, 56, 323-324.	1.5	7
56	Ectopic Craniopharyngioma. Klinische Padiatrie, 2011, 223, 176-177.	0.6	25
57	Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome. American Journal of Human Genetics, 2010, 86, 279-284.	6.2	288
58	Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes and Cancer, 2010, 49, 176-181.	2.8	96
59	Neonatal cholestasis and glucoseâ€6â€Pâ€dehydrogenase deficiency. Pediatric Blood and Cancer, 2010, 54, 758-760.	1.5	9
60	Cribriform Neuroepithelial Tumor (CRINET): A Nonrhabdoid Ventricular Tumor With INI1 Loss and Relatively Favorable Prognosis. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1249-1255.	1.7	92
61	Neuroonkologie. , 2009, , 215-239.		0
62	Erythrocytapheresis: Do Not Forget a Useful Therapy!. Transfusion Medicine and Hemotherapy, 2008, 35, 24-30.	1.6	10
63	Non-linkage of familial rhabdoid tumors toSMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatric Blood and Cancer, 2006, 47, 273-278.	1.5	65
64	Expression of SOX9 and SOX10 in Central Neuroepithelial Tumor. Journal of Neuro-Oncology, 2006, 80, 151-155.	2.9	48
65	Sox group E gene expression distinguishes different types and maturational stages of glial cells in developing chick and mouse. Developmental Brain Research, 2005, 157, 209-213.	1.7	31
66	Long-term treatment with deferiprone in a L1 veteran. European Journal of Haematology, 2005, 74, 523-525.	2.2	4
67	Transcription factor NF-ÎºB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia, 2000, 14, 399-402.	7.2	252
68	Molecular mechanisms of constitutive NF-ÎºB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene, 1999, 18, 943-953.	5.9	265
69	Gremlins of all brain tumors: germinomas and nongerminomatous germ cell tumors. Critical Reviews in Neurosurgery: CR, 1998, 8, 1-5.	0.2	1